{"id":"chlorproethazine","rwe":[{"pmid":"40020517","year":"2025","title":"Phenothiazines boost host control of Mycobacterium avium infection in primary human macrophages.","finding":"","journal":"Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie","studyType":"Clinical Study"},{"pmid":"32124458","year":"2020","title":"Photodermatitis from topical phenothiazines: A case series.","finding":"","journal":"Contact dermatitis","studyType":"Clinical Study"},{"pmid":"18201351","year":"2008","title":"Photocontact allergic and phototoxic studies of chlorproethazine.","finding":"","journal":"Photodermatology, photoimmunology & photomedicine","studyType":"Clinical Study"},{"pmid":"11417527","year":"2001","title":"Contact sensitization to chlorproethazine can induce persistent light reaction and cross-photoreactions to other phenothiazines.","finding":"","journal":"Contact dermatitis","studyType":"Clinical Study"},{"pmid":"8210139","year":"1993","title":"[Retentive photosensitivity induced by chlorproethazine].","finding":"","journal":"Annales de dermatologie et de venereologie","studyType":"Clinical Study"}],"tags":[{"label":"chlorproethazine","category":"class"},{"label":"Small Molecule","category":"modality"},{"label":"D(3) dopamine receptor","category":"target"},{"label":"DRD3","category":"gene"},{"label":"DRD2","category":"gene"},{"label":"DRD4","category":"gene"},{"label":"N05AA07","category":"atc"},{"label":"Active","category":"status"},{"label":"Central Nervous System Agents","category":"pharmacology"},{"label":"Muscle Relaxants, Central","category":"pharmacology"},{"label":"Neuromuscular Agents","category":"pharmacology"},{"label":"Peripheral Nervous System Agents","category":"pharmacology"}],"phase":"phase_2","safety":{},"trials":[],"aliases":[],"patents":[],"pricing":[],"_fixedAt":"2026-03-30T15:49:26.634384","allNames":"2-chloro-10-(3-diethylaminopropyl)phenothiazine","offLabel":[],"synonyms":["chlorproethazine","RP 4909","2-Chloro-10-(3-diethylaminopropyl)phenothiazine"],"timeline":[],"aiSummary":"2-Chloro-10-(3-Diethylaminopropyl)Phenothiazine, also known as Chlorproethazine, is a small molecule targeting the D(3) dopamine receptor. It belongs to the chlorproethazine drug class but its commercial status, including patent and generic availability, is unknown. The FDA approval status for Chlorproethazine is also unclear. As a dopamine receptor antagonist, it is likely used to treat conditions related to dopamine dysregulation, but specific approved indications are not available. Further research is needed to understand its pharmacokinetic properties and safety considerations.","approvals":[],"brandName":"2-Chloro-10-(3-Diethylaminopropyl)Phenothiazine","ecosystem":[],"mechanism":{"target":"D(4) dopamine receptor, D(2) dopamine receptor, D(3) dopamine receptor","targets":[{"gene":"DRD3","source":"DrugCentral","target":"D(3) dopamine receptor","protein":"D(3) dopamine receptor","isPrimary":true,"activityType":"Ki","activityValue":7.987},{"gene":"DRD2","source":"DrugCentral","target":"D(2) dopamine receptor","protein":"D(2) dopamine receptor"},{"gene":"DRD4","source":"DrugCentral","target":"D(4) dopamine receptor","protein":"D(4) dopamine receptor"}],"modality":"Small Molecule","drugClass":"chlorproethazine","explanation":"Imagine dopamine as a key that unlocks a door. The D(3) receptor is like the lock on that door. When dopamine binds to the receptor, it can trigger various effects in the body. Chlorproethazine acts like a lockout device, preventing dopamine from binding to the receptor and thereby reducing its effects.","oneSentence":"Chlorproethazine works by blocking the action of dopamine at the D(3) receptor, which can help regulate various physiological processes.","technicalDetail":"Chlorproethazine exerts its effects by competitively antagonizing the D(3) dopamine receptor, a subtype of dopamine receptor that plays a critical role in regulating various physiological processes, including reward, motivation, and movement."},"commercial":{},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/619","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=CHLORPROETHAZINE","fields":["publications"],"source":"PubMed/NCBI"}],"_enrichedAt":"2026-03-30T09:34:53.246798","biosimilars":[],"competitors":[{"drugName":"chlorpromazine","drugSlug":"chlorpromazine","fdaApproval":"1957-09-18","patentStatus":"Unknown","relationship":"same-class"},{"drugName":"levomepromazine","drugSlug":"levomepromazine","fdaApproval":"","patentStatus":"Unknown","relationship":"same-class"},{"drugName":"promazine","drugSlug":"promazine","fdaApproval":"1956-04-13","genericCount":1,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"acepromazine","drugSlug":"acepromazine","fdaApproval":"","relationship":"same-class"},{"drugName":"triflupromazine","drugSlug":"triflupromazine","fdaApproval":"1957-09-16","patentStatus":"Unknown","relationship":"same-class"}],"dataSources":[{"url":"https://drugcentral.org","name":"DrugCentral","fields":["indications","contraindications","safety","target","drugInteractions"],"retrievedDate":"2026-04-07"}],"genericName":"chlorproethazine","indications":{"approved":[],"offLabel":[],"pipeline":[]},"_fixedFields":["primaryTarget"],"drugCategory":"active","labelChanges":[],"relatedDrugs":[{"drugId":"chlorpromazine","brandName":"chlorpromazine","genericName":"chlorpromazine","approvalYear":"1957","relationship":"same-class"},{"drugId":"levomepromazine","brandName":"levomepromazine","genericName":"levomepromazine","approvalYear":"","relationship":"same-class"},{"drugId":"promazine","brandName":"promazine","genericName":"promazine","approvalYear":"1956","relationship":"same-class"},{"drugId":"acepromazine","brandName":"acepromazine","genericName":"acepromazine","approvalYear":"","relationship":"same-class"},{"drugId":"triflupromazine","brandName":"triflupromazine","genericName":"triflupromazine","approvalYear":"1957","relationship":"same-class"}],"trialDetails":[],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"administration":{},"crossReferences":{"NDDF":"005317","UNII":"960NX27Z07","CHEBI":"CHEBI:135464","INN_ID":"1147","RXNORM":"59860","UMLSCUI":"C0164858","ChEMBL_ID":"CHEMBL52125","KEGG_DRUG":"D07308","DRUGBANK_ID":"DB13382","PUBCHEM_CID":"65750","MESH_SUPPLEMENTAL_RECORD_UI":"C054028"},"formularyStatus":[],"_enricherVersion":"v2","developmentCodes":[],"ownershipHistory":[],"publicationCount":12,"therapeuticAreas":["Other"],"atcClassification":{"source":"DrugCentral","atcCode":"N05AA07","allCodes":["N05AA07"]},"biosimilarFilings":[],"recentPublications":[{"date":"2025 Apr","pmid":"40020517","title":"Phenothiazines boost host control of Mycobacterium avium infection in primary human macrophages.","journal":"Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie"},{"date":"2020 Jul","pmid":"32124458","title":"Photodermatitis from topical phenothiazines: A case series.","journal":"Contact dermatitis"},{"date":"2008 Feb","pmid":"18201351","title":"Photocontact allergic and phototoxic studies of chlorproethazine.","journal":"Photodermatology, photoimmunology & photomedicine"},{"date":"2001 Jun","pmid":"11417527","title":"Contact sensitization to chlorproethazine can induce persistent light reaction and cross-photoreactions to other phenothiazines.","journal":"Contact dermatitis"},{"date":"1993","pmid":"8210139","title":"[Retentive photosensitivity induced by chlorproethazine].","journal":"Annales de dermatologie et de venereologie"}],"companionDiagnostics":[],"genericManufacturerList":[],"status":"active","companyName":"","companyId":"","modality":"Small molecule","firstApprovalDate":"","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"partial","dataCompleteness":{"mechanism":true,"indications":false,"safety":false,"trials":false,"score":1}}